Tao Tao, Del Valle Alfonso
The Toronto Institute For Reproductive Medicine, Toronto, ON, Canada.
J Assist Reprod Genet. 2008 Jul;25(7):287-96. doi: 10.1007/s10815-008-9236-z. Epub 2008 Aug 1.
To review the recent progress in human oocyte and ovarian tissue cryopreservation, and in the application of these two technologies for preserving female fertility of patients who are undergoing cancer treatment.
The literature on human oocyte and ovarian tissue freezing was searched with PubMed. The scientific background, current developments and potential future applications of these two methods were reviewed.
Chemotherapy and/or radiotherapy can induce premature ovarian failure in most of female cancer patients. Consequently, there has been a greater need for options to preserve the reproductive potential of these individuals. However, options are somewhat limited currently, particularly following aggressive chemotherapy and/or radiotherapy treatment protocols. In recent years, there have been considerable advances in the cryopreservation of human oocytes and ovarian tissue. For women facing upcoming cancer therapies, cryopreservation of ovarian tissue and oocytes is a technology that holds promise for banking reproductive potential for the future. Recent laboratory modifications have resulted in improved oocyte survival, oocyte fertilization, and pregnancy rates from frozen-thawed oocytes in IVF. This suggests potential for clinical application.
In the case of patients who are facing infertility due to cancer therapy, oocyte cryopreservation may be one of the few options available. Ovarian tissue cryopreservation can only be recommended as an experimental protocol in carefully selected patients. In ovarian tissue transplantation, more research is needed in order to enhance the revascularization process with the goal of reducing the follicular loss that takes place after tissue grafting. These technologies are still investigational, although tremendous progress has been made. The availability of such treatment will potentially lead to its demand not only from patients with cancer but also from healthy women who chose to postpone childbearing until later in life and therefore wish to retain their fertility.
回顾人类卵母细胞和卵巢组织冷冻保存的最新进展,以及这两种技术在为接受癌症治疗的患者保留生育能力方面的应用。
通过PubMed搜索有关人类卵母细胞和卵巢组织冷冻保存的文献。对这两种方法的科学背景、当前进展及潜在的未来应用进行综述。
化疗和/或放疗可导致大多数女性癌症患者出现卵巢早衰。因此,更需要有方法来保留这些患者的生殖潜能。然而,目前选择有限,尤其是在采用积极的化疗和/或放疗治疗方案之后。近年来,人类卵母细胞和卵巢组织冷冻保存取得了显著进展。对于面临即将到来的癌症治疗的女性而言,卵巢组织和卵母细胞冷冻保存是一项有望为未来储存生殖潜能的技术。近期实验室的改进已使体外受精中冻融卵母细胞的存活、受精及妊娠率得到提高。这表明其具有临床应用潜力。
对于因癌症治疗而面临不孕的患者,卵母细胞冷冻保存可能是少数可用的选择之一。卵巢组织冷冻保存仅可在经过精心挑选的患者中作为实验方案推荐。在卵巢组织移植方面,为了加强血管再生过程,以减少组织移植后发生的卵泡损失,还需要更多研究。这些技术仍处于研究阶段,尽管已取得了巨大进展。这种治疗方法的可用性可能不仅会引发癌症患者的需求,还会引发那些选择推迟生育至晚年、因而希望保留生育能力的健康女性的需求。